iRadimed Sees Q3 Adj EPS $0.54-$0.59 vs $0.52 Est; Sees Sales $23.000M-$24.500M vs $23.650M Est
iRadimed (NASDAQ:IRMD) is looking for Q3 Adj EPS of $0.54-$0.59 vs $0.52 analyst estimate. sees sales of $23.000 million-$24.500 million vs $23.650 million analyst estimate.
iRadimed expects to earn a bit more per share than people guessed, but sales might come in lower than expected. When a company beats on profit but misses on sales, watch to see if they're just cutting costs or if their business is actually growing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.